- Home
- MRCC vs TNYA Comparison
MRCC vs TNYA Comparison
Compare MRCC & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | TNYA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.2M | 159.6M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRCC | TNYA |
|---|---|---|
| Price | $6.56 | $0.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $8.00 | $7.80 |
| AVG Volume (30 Days) | 135.4K | ★ 5.0M |
| Earning Date | 02-27-2026 | 11-10-2025 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $0.36 |
| 52 Week High | $8.85 | $2.35 |
Technical Indicators
Market Signals| Indicator | MRCC | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 39.64 |
| Support Level | $6.08 | $0.72 |
| Resistance Level | $6.80 | $0.82 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 92.31 | 64.88 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.